Zhou Li, He Xiao-Dong, Cui Quan-Cai, Zhou Wei-Xun, Qu Qiang, Zhou Rou-Li, Rui Jing-An, Yu Jian-Chun
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100032, China.
Cancer Lett. 2008 Jun 18;264(2):209-17. doi: 10.1016/j.canlet.2008.01.025. Epub 2008 Mar 10.
LAPTM4B was proven to overexpress in hepatocellular carcinoma and relate to differentiation. We immunohistochemically investigated the expression and potential clinicopathological and prognostic significance of LAPTM4B encoded protein, LAPTM4B-35, in extrahepatic cholangiocarcinoma (EHCC) for specimens from consecutive 81 patients. LAPTM4B-35 staining was positive in cancer tissues from 59 patients (72.8%), including 12 with score 1, 22 with score 2 and 25 with score 3. No positive staining was found in non-cancer epithelia. The staining score in cancer tissues was not only significantly associated with TNM staging, histological grade, perineural and lymph node invasion (P<0.05), but also of comprehensive prognostic implications, including integrated estimation with CA19-9. These data established that LAPTM4B-35 positively expressed in a great portion of EHCC and might be a novel molecular maker of progression, invasiveness and poor prognosis.
LAPTM4B已被证实在肝细胞癌中过表达且与分化相关。我们采用免疫组化方法研究了连续81例肝外胆管癌（EHCC）标本中LAPTM4B编码蛋白LAPTM4B - 35的表达情况及其潜在的临床病理和预后意义。LAPTM4B - 35染色在59例患者（72.8%）的癌组织中呈阳性，其中12例评分为1分，22例评分为2分，25例评分为3分。在非癌上皮中未发现阳性染色。癌组织中的染色评分不仅与TNM分期、组织学分级、神经周围浸润和淋巴结转移显著相关（P<0.05），而且具有综合预后意义，包括与CA19 - 9的综合评估。这些数据表明LAPTM4B - 35在大部分EHCC中呈阳性表达，可能是进展、侵袭性和不良预后的新型分子标志物。
